| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/DMR.5610090303 |
| P698 | PubMed publication ID | 8187606 |
| P2093 | author name string | Patrono C | |
| Daví G | |||
| P2860 | cites work | The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results | Q24514937 |
| Final report on the aspirin component of the ongoing Physicians' Health Study | Q29619461 | ||
| Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study | Q34247562 | ||
| Estimated rate of thromboxane secretion into the circulation of normal humans | Q34521662 | ||
| The Use of Aspirin in Ischemic Heart Disease | Q35176153 | ||
| "Mirror image" antagonists of thrombin-induced platelet activation based on thrombin receptor structure | Q35597476 | ||
| Antiplatelet drugs and prevention of macrovascular disease in diabetes mellitus | Q36058883 | ||
| The treatment of diabetic retinopathy: a view for the internist | Q36257256 | ||
| Micro-albuminuria and large vessel disease in diabetes | Q36272682 | ||
| Platelet function in diabetes mellitus | Q36335824 | ||
| Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects | Q36984424 | ||
| Transforming growth factor-beta regulates production of proteoglycans by mesangial cells | Q38147084 | ||
| Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back | Q38241943 | ||
| The pathogenesis of atherosclerosis--an update | Q39726917 | ||
| Dipyridamole | Q39765543 | ||
| Clinical pharmacology of platelet cyclooxygenase inhibition | Q39849855 | ||
| Thromboxane biosynthesis and platelet function in type I diabetes mellitus | Q41429378 | ||
| Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes | Q43511438 | ||
| A prospective study of mortality among middle-aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics) I: Causes and death rates | Q44208466 | ||
| Long-lived enzymatic metabolites of thromboxane B2 in the human circulation | Q44710166 | ||
| Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase | Q44955459 | ||
| Thromboxane biosynthesis and platelet function in type II diabetes mellitus | Q45056796 | ||
| Low-molecular-weight heparin and other new antithrombotic drugs | Q47413603 | ||
| Platelet-inhibitor treatment of diabetic nephropathy: a 10-year prospective study. | Q51626955 | ||
| Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus | Q52859992 | ||
| Role of platelets in pathogenesis of diabetic retinopathy. | Q54149887 | ||
| Ticlopidine Treatment Reduces the Progression of Nonproliferative Diabetic Retinopathy | Q56455080 | ||
| Thrombosis in Unstable Angina | Q56987032 | ||
| Thromboxane synthesis and action within the kidney | Q57704497 | ||
| Synthesis and structure of the platelet aggregation factor thromboxane A2 | Q59062122 | ||
| Elevated Urinary Prostaglandin Excretion and the Effect of Indomethacin on Renal Function in Incipient Diabetic Nephropathy | Q60218057 | ||
| Low-dose aspirin and stroke. "It ain't necessarily so" | Q67564601 | ||
| Thromboxane in the pathogenesis of glomerular injury in diabetes | Q67595214 | ||
| Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs | Q67903664 | ||
| A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke | Q68016827 | ||
| Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators | Q68021310 | ||
| Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disea | Q68071745 | ||
| Prospective study of microalbuminuria as predictor of mortality in NIDDM | Q68127291 | ||
| Clinical trials and meta-analysis. What do they do for us? | Q68175770 | ||
| Does microaneurysm count reflect severity of early diabetic retinopathy? | Q69555097 | ||
| Renal scintigraphy and survival of indium-111-labelled platelets in patients with diabetic nephropathy | Q69577199 | ||
| Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man | Q69663489 | ||
| Fractional conversion of thromboxane A2 and B2 to urinary 2,3-dinor-thromboxane B2 and 11-dehydrothromboxane B2 in the cynomolgus monkey | Q69663491 | ||
| The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years | Q70330516 | ||
| Picotamide, a dual TXB synthetase inhibitor and TXB receptor antagonist, reduces exercise-induced albuminuria in microalbuminuric patients with NIDDM | Q70530959 | ||
| Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects | Q71172266 | ||
| Specific thromboxane synthetase inhibition and albumin excretion rate in insulin-dependent diabetes | Q72580517 | ||
| Microalbuminuria predicts mortality in non-insulin-dependent diabetics | Q72841273 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 177-188 | |
| P577 | publication date | 1993-10-01 | |
| P1433 | published in | Diabetes/metabolism reviews | Q27710714 |
| P1476 | title | Antiplatelet agents in the prevention of diabetic vascular complications | |
| P478 | volume | 9 |
| Q28222271 | Achieving American Diabetes Association goals in HIV-seropositive patients with diabetes mellitus |
| Q24246789 | Adenosin-diphosphate (ADP) receptor antagonists (clopidogrel, ticlopidine) for the prevention of cardiovascular disease in type 2 diabetes mellitus |
| Q46926316 | Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects |
| Q35437774 | Endothelial and platelet markers in diabetes mellitus type 2 |
| Q35736714 | High-risk type-2 diabetes mellitus patients, without prior ischemic events, have normal blood platelet functionality profiles: a cross-sectional study |
| Q41687438 | Multifactorial aspects of the treatment of the type II diabetic patient |
| Q44392609 | Role for thromboxane A2 from glomerular thrombi in nephropathy with type 2 diabetic rats |
| Q42913738 | Which diabetic patients should be taking aspirin? |
Search more.